Skip to Content

Join the 'Xgeva' group to help and get support from people like you.

Xgeva News

FDA Approves Xgeva (denosumab) for the Prevention of Skeletal-Related Events in Patients with Multiple Myeloma

Posted 10 Jan 2018 by Drugs.com

THOUSAND OAKS, Calif., Jan. 5, 2018 /PRNewswire/ – Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Xgeva (denosumab) to expand the currently approved indication for the prevention of skeletal-related events in patients with bone metastases from solid tumors to include patients with ...

Breast Cancer Drugs Battle Disease's Return

Posted 9 Dec 2015 by Drugs.com

WEDNESDAY, Dec. 9, 2015 – A pair of drugs already on the market appear to reduce the recurrence of breast cancer in women who've already undergone treatment, two new clinical trials show. The chemotherapy drug capecitabine (Afinitor) seems to reduce by nearly a third the risk of breast cancer recurrence if women receive the drug following surgery to remove their cancer, researchers were to ...

Strong Bones After 50? Women May Not Need Next Test Until 65

Posted 9 Jun 2015 by Drugs.com

TUESDAY, June 9, 2015 – A postmenopausal woman who is 50 and still shows "normal" readings on her bone density test may not need her next such test for 10 or even 15 years, a new study finds. However, researchers led by Dr. Margaret Gourlay of the University of North Carolina at Chapel Hill stressed that younger women who do show signs of bone loss are at high risk for a major fracture, and do ...

FDA Approves Xgeva (denosumab) for Hypercalcemia of Malignancy Refractory to Bisphosphonate Therapy

Posted 8 Dec 2014 by Drugs.com

THOUSAND OAKS, Calif., Dec. 8, 2014 /PRNewswire/ – Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for Xgeva (denosumab) for the treatment of hypercalcemia of malignancy (HCM) refractory to bisphosphonate therapy. Xgeva was approved and granted Orphan Drug Designation by the FDA, which is reserved for drugs that are intended for ...

Osteoporosis Drugs Work, But Review Finds No Clear Winner

Posted 8 Sep 2014 by Drugs.com

MONDAY, Sept. 8, 2014 – Many osteoporosis drugs cut women's risk of suffering a bone fracture, though it's not clear whether any one medication works better than others, a new research review finds. Reporting Sept. 8 in Annals of Internal Medicine, researchers said that for women with the bone-thinning disease osteoporosis, various drugs cut the risk of a spine fracture by 40 to 60 percent, ...

FDA Approves Xgeva to Treat Giant Cell Tumor of the Bone

Posted 13 Jun 2013 by Drugs.com

June 13, 2013 – The U.S. Food and Drug Administration today expanded the approved use of Xgeva (denosumab) to treat adults and some adolescents with giant cell tumor of the bone (GCTB), a rare and usually non-cancerous tumor. GCTB generally occurs in adults between the ages of 20 and 40 years. In most cases, GCTB does not spread to other parts of the body but destroys normal bone as it grows, ...

Ask a Question

Further Information

Related Condition Support Groups

Osteolytic Bone Metastases of Solid Tumors, Giant Cell Tumor of Bone, Osteolytic Bone Lesions of Multiple Myeloma, Hypercalcemia of Malignancy

Xgeva Patient Information at Drugs.com